No triggers rgs4 degradation to coordinate angiogenesis and cardiomyocyte growth

Journal of Clinical Investigation

Volumn 123, Issue 4, 2013, Pages 1718-1731

  Jaba, Irina M ^a   Zhuang, Zhen W ^a   Li, Na ^a   Jiang, Yifeng ^b   Martin, Kathleen A ^a,b   Sinusas, Albert J ^a,b   Papademetris, Xenophon ^c   Simons, Michael ^a,b   Sessa, William C ^b   Young, Lawrence H ^a   Tirziu, Daniela ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Diagnostic Radiology ^*  (United States)

^c Biomedical Engineering   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN C1; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACENTAL GROWTH FACTOR; PROTEIN KINASE B; RGS4 PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL GROWTH; CONTROLLED STUDY; GENE OVEREXPRESSION; HEART BLOOD VESSEL; HEART MUSCLE CELL; HEART SIZE; HEART VENTRICLE HYPERTROPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REGULATORY MECHANISM;

ADAPTATION, BIOLOGICAL; ANIMALS; CELL ENLARGEMENT; CELLS, CULTURED; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; HEART VENTRICLES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCYTES, CARDIAC; NEOVASCULARIZATION, PHYSIOLOGIC; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PREGNANCY PROTEINS; PROTEINS; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RGS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84875843715     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI65112     Document Type: Article

References (72)

1. Tirziu D, Giordano FJ, Simons M. Cell communications in the heart. Circulation. 2010;122(9):928-937.
2. Tirziu D, et al. Myocardial hypertrophy in the absence of external stimuli is induced by angiogenesis in mice. J Clin Invest. 2007;117(11):3188- 3197.
3. Hao J, et al. Regulation of cardiomyocyte signaling by RGS proteins: Differential selectivity towards G proteins and susceptibility to regulation. J Mol Cell Cardiol. 2006;41(1):51-61.
4. Mittmann C, et al. Expression of ten RGS proteins in human myocardium: Functional characterization of an upregulation of RGS4 in heart failure. Cardiovasc Res. 2002;55(4):778-786.
5. Owen VJ, et al. Expression of RGS3, RGS4 and Gi alpha 2 in acutely failing donor hearts and end-stage heart failure. Eur Heart J. 2001;22(12):1015-1020.
6. Lee MJ, et al. RGS4 and RGS5 are in vivo substrates of the N-end rule pathway. Proc Natl Acad Sci U S A. 2005;102(42):15030-15035.
7. Davydov IV, Varshavsky A. RGS4 is arginylated and degraded by the N-end rule pathway in vitro. J Biol Chem. 2000;275(30):22931-22941.
8. Hu RG, et al. The N-end rule pathway as a nitric oxide sensor controlling the levels of multiple regulators. Nature. 2005;437(7061):981-986.
9. Berman DM, Gilman AG. Mammalian RGS proteins: Barbarians at the gate. J Biol Chem. 1998; 273(3):1269-1272.
10. De Vries L, Zheng B, Fischer T, Elenko E, Farquhar MG. The regulator of G protein signaling family. Annu Rev Pharmacol Toxicol. 2000;40:235-271.
11. Lambert NA, et al. Regulators of G-protein signaling accelerate GPCR signaling kinetics and govern sensitivity solely by accelerating GTPase activity. Proc Natl Acad Sci U S A. 2010;107(15):7066-7071.
12. Hubbard KB, Hepler Jr. Cell signalling diversity of the Gqalpha family of heterotrimeric G proteins. Cell Signal. 2006;18(2):135-150.
13. Tirziu D, Simons M. Endothelium-driven myocardial growth or nitric oxide at the crossroads. Trends Cardiovasc Med. 2008;18(8):299-305.
14. Sugden PH, Clerk A. Regulation of the ERK subgroup of MAP kinase cascades through G proteincoupled receptors. Cell Signal. 1997;9(5):337-351.
15. van Berlo JH, Maillet M, Molkentin JD. Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Invest. 2013;123(1):37-45.
16. Dupre DJ, Robitaille M, Rebois RV, Hebert TE. The role of Gbetagamma subunits in the organization, assembly, and function of GPCR signaling complexes. Annu Rev Pharmacol Toxicol. 2009;49:31-56.
17. Kerchner KR, et al. Differential sensitivity of phosphatidylinositol 3-kinase p110gamma to isoforms of G protein betagamma dimers. J Biol Chem. 2004; 279(43):44554-44562.
18. Naga Prasad SV, Esposito G, Mao L, Koch WJ, Rockman HA. Gbetagamma-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy. J Biol Chem. 2000; 275(7):4693-4698.
19. Ma XMBlenis J. Molecular mechanisms of mTORmediated translational control. Nat Rev Mol Cell Biol. 2009;10(5):307-318.
20. Autiero M, et al. Role of PlGF in the intra-and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med. 2003;9(7):936-943.
21. Carmeliet P, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001;7(5):575-583.
22. Li W, et al. High-resolution quantitative computed tomography demonstrating selective enhancement of medium-size collaterals by placental growth factor-1 in the mouse ischemic hindlimb. Circulation. 2006;113(20):2445-2453.
23. Luttun A, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med. 2002;8(8):831-840.
24. Roncal C, et al. Beneficial effects of prolonged systemic administration of PlGF on late outcome of post-ischaemic myocardial performance. J Pathol. 2008;216(2):236-244.
25. Accornero F, et al. Placental growth factor regulates cardiac adaptation and hypertrophy through a paracrine mechanism. Circ Res. 2011;109(3):272-280.
26. Ni YG, et al. Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling. Circulation. 2006;114(11):1159-1168.
27. Rengo G, et al. Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation. 2009; 119(1):89-98.
28. Camps M, et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med. 2005; 11(9):936-943.
29. Wang C, Jayadev S, Escobedo JA. Identification of a domain in the angiotensin II type 1 receptor determining Gq coupling by the use of receptor chimeras. J Biol Chem. 1995;270(28):16677-16682.
30. Molkentin JD, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93(2):215-228.
31. Lunde IG, Kvaloy H, Austbo B, Christensen G, Carlson CR. Angiotensin II and norepinephrine activate specific calcineurin-dependent NFAT transcription factor isoforms in cardiomyocytes. J Appl Physiol. 2011;111(5):1278-1289.
32. Furfine ES, et al. Potent and selective inhibition of human nitric oxide synthases. Selective inhibition of neuronal nitric oxide synthase by S-methyl-Lthiocitrulline and S-ethyl-L-thiocitrulline. J Biol Chem. 1994;269(43):26677-26683.
33. Flaherty MP, et al. eNOS deficient mice develop progressive cardiac hypertrophy with altered cytokine and calcium handling protein expression. Cardiovasc Toxicol. 2007;7(3):165-177.
34. Tomanek RJ, Busch TL. Coordinated capillary and myocardial growth in response to thyroxine treatment. Anat Rec. 1998;251(1):44-49.
35. Gaasch WH. Left ventricular radius to wall thickness ratio. Am J Cardiol. 1979;43(6):1189-1194.
36. Sugishita Y, Koseki S, Matsuda M, Yamaguchi T, Ito I. Myocardial mechanics of athletic hearts in comparison with diseased hearts. Am Heart J. 1983;105(2):273-280.
37. Weiner RB, Baggish AL. Exercise-induced cardiac remodeling. Prog Cardiovasc Dis. 2012;54(5):380-386.
38. Walsh K, Shiojima I. Cardiac growth and angiogenesis coordinated by intertissue interactions. J Clin Invest. 2007;117(11):3176-3179.
39. Guo Y, et al. Genetic background, gender, age, body temperature, and arterial blood pH have a major impact on myocardial infarct size in the mouse and need to be carefully measured and/or taken into account: Results of a comprehensive analysis of determinants of infarct size in 1,074 mice. Basic Res Cardiol. 2012;107(5):288.
40. Bry M, et al. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation. 2010;122(17):1725-1733.
41. Barouch LA, et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature. 2002;416(6878):337-339.
42. Balligand JL, Feron O, Dessy C. eNOS activation by physical forces: From short-term regulation of contraction to chronic remodeling of cardiovascular tissues. Physiol Rev. 2009;89(2):481-534.
43. Ahmad S, et al. Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis. Circ Res. 2006;99(7):715-722.
44. Tesmer VM, Kawano T, Shankaranarayanan A, Kozasa T, Tesmer JJ. Snapshot of activated G proteins at the membrane: The Galphaq-GRK2-Gbetagamma complex. Science. 2005;310(5754):1686-1690.
45. Zhong H, et al. A spatial focusing model for G protein signals. Regulator of G protein signaling (RGS) protien-mediated kinetic scaffolding. J Biol Chem. 2003;278(9):7278-7284.
46. Takimoto E, et al. Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest. 2009;119(2):408-420.
47. Tamirisa P, Blumer KJ, Muslin AJ. RGS4 inhibits G-protein signaling in cardiomyocytes. Circulation. 1999;99(3):441-447.
48. Tokudome T, et al. Regulator of G-protein signaling subtype 4 mediates antihypertrophic effect of locally secreted natriuretic peptides in the heart. Circulation. 2008;117(18):2329-2339.
49. Rogers JH, et al. RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload. J Clin Invest. 1999;104(5):567-576.
50. Rogers JH, et al. RGS4 reduces contractile dysfunction and hypertrophic gene induction in Galpha q overexpressing mice. J Mol Cell Cardiol. 2001; 33(2):209-218.
51. D'Angelo DD, et al. Transgenic Galphaq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci U S A. 1997;94(15):8121-8126.
52. Mende U, et al. Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc Natl Acad Sci U S A. 1998;95(23):13893-13898.
53. Xie Y, et al. Breast cancer migration and invasion depend on proteasome degradation of regulator of G-protein signaling 4. Cancer Res. 2009; 69(14):5743-5751.
54. Kirui JK, et al. Gbetagamma signaling promotes breast cancer cell migration and invasion. J Pharmacol Exp Ther. 2010;333(2):393-403.
55. Hamed EA, Zakhary MM, Maximous DW. Apoptosis, angiogenesis, inflammation, and oxidative stress: Basic interactions in patients with early and metastatic breast cancer. J Cancer Res Clin Oncol. 2012;138(6):999-1009.
56. Sjogren B, Neubig RR. Thinking outside of the "RGS box": New approaches to therapeutic targeting of regulators of G protein signaling. Mol Pharmacol. 2010;78(4):550-557.
57. Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther. 2009;122(3):216-238.
58. Fiedler B, et al. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci U S A. 2002;99(17):11363-11368.
59. Fiedler B, Wollert KC. Interference of antihypertrophic molecules and signaling pathways with the Ca2+-calcineurin-NFAT cascade in cardiac myocytes. Cardiovasc Res. 2004;63(3):450-457.
60. Koitabashi N, et al. Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition. J Mol Cell Cardiol. 2010; 48(4):713-724.
61. Wilkins BJ, et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res. 2004;94(1):110-118.
62. DiPalma T, et al. The placenta growth factor gene of the mouse. Mamm Genome. 1996;7(1):6-12.
63. Chang B, Mathew R, Palmer LS, Valderrama E, Trachtman H. Nitric oxide in obstructive uropathy: Role of endothelial nitric oxide synthase. J Urol. 2002;168(4 Pt 2):1801-1804.
64. Kemuriyama T, et al. Endogenous angiotensin II has fewer effects but neuronal nitric oxide synthase has excitatory effects on renal sympathetic nerve activity in salt-sensitive hypertension-induced heart failure. J Physiol Sci. 2009;59(4):275-281.
65. Komers R, Lindsley JN, Oyama TT, Anderson S. Effects of long-term inhibition of neuronal nitric oxide synthase (NOS1) in uninephrectomized diabetic rats. Nitric Oxide. 2004;11(2):147-155.
66. Graveleau C, et al. Mouse and human resistins impair glucose transport in primary mouse cardiomyocytes, and oligomerization is required for this biological action. J Biol Chem. 2005; 280(36):31679-31685.
67. Tang M, et al. Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts. Cardiovasc Res. 2010; 88(3):424-433.
68. Zagorchev L, et al. Micro computed tomography for vascular exploration. J Angiogenes Res. 2010;2:7.
69. Jiang Y, Zhuang Z, Sinusas AJ, Papademetris X. Vascular tree reconstruction by minimizing a physiological functional cost. Conf Comput Vis Pattern Recognit Workshops. 2010;178-185.
70. Frangi A, Niessen W, Vincken K, Viergever M. Multiscale vessel enhancement filtering. In: Wells W, Colchester A, Delp S, eds. Medical Image Computing and Computer-Assisted Interventation 1998. Berlin, Germany: Springer Berlin; 1998:130-137.
71. Lee TC, Kashyap RL, Chu CN. Building skeleton models via 3-D medial surface axis thinning algorithms. CVGIP: Graphical Models and Image Processing. 1994;56(6):462-478.
72. Murray CD. The physiological principle of minimum work: I. The vascular system and the cost of blood volume. Proc Natl Acad Sci U S A. 1926; 12(3):207-214.